Mainz Biomed 定价 $8M 股票发行以资助癌症检测测试研究。 Mainz Biomed prices $8M stock offering to fund cancer detection test research.

Mainz Biomed是一家开发早期癌症检测检测的公司,其价格为800万美元的后续股票供应。 Mainz Biomed, a company that develops early cancer detection tests, has priced a $8.0 million follow-on stock offering. 提供包括1 367 521个单位,每单位价格为5.85美元,包括普通股份和许可证。 The offering includes 1,367,521 units, each priced at $5.85, comprising ordinary shares and warrants. 这笔资金将支持该公司的研究与开发,包括直肠癌测试、ColoAlert、以及胰腺癌筛查。 The funds will support the company’s research and development, including their colorectal cancer test, ColoAlert®, and a pancreatic cancer screening test. 预计将于2024年12月16日关闭。 The offering is expected to close on December 16, 2024.